Moriah Gildart Turcotte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Moriah Gildart Turcotte has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Jinliang Li
Stanford University, United States
5 shared publications - Kimberly L. Dodge-Kafka
University of Connecticut Health Center
5 shared publications - Michael S. Kapiloff
Stanford University
5 shared publications - Abraham L. Bayer
Department of Immunology, School of Medicine (R.E., Z.R., C.K., S.S., A.L.B., P.A.), Tufts University, Boston, MA
3 shared publications - Pilar Alcaide
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 shared publications - Sofia M. Possidento
UCONN Health, United States
3 shared publications
Latest Publications
- Open Access
Gene therapy targeting of AKAP6β-CaMKII signalosomes improves myocardial inflammation and heart failure in a swine model of cardiometabolic syndrome
Background: Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is associated with systemic and cardiac inflammation and diastolic dysfunction. A-kinase anchoring protein 6β (AKAP6β) is a scaffold protein located at the cardiomyocyte outer nuclear membrane that promotes pathological cardiac remodeling via the recruitment of multiple regulatory proteins including protein kinases. In mice, adeno-associated virus (AAV) mediated expression of a peptide based upon a kinase binding domain (KBD) within AKAP6β inhibited the development of heart failure due to chronic pressure overload. Whether KBD expression can also inhibit the development of cardiometabolic heart failure is unknown, and if so, the mechanism of KBD action in HFpEF has yet to be explored. Methods: The efficacy of a cardiotropic self-complementary AAV gene therapy that expresses the AKAP6β KBD peptide (AAV9sc.KBD) was tested in a female Ossabaw swine model of cardiometabolic syndrome and HFpEF. Single nucleus and bulk RNA sequencing of swine heart tissue and immunoprecipitation-mass spectrometry, live cell imaging, and biochemical assays using primary rat cardiomyocytes were employed to study KBD mechanism of action. Results: AAV9sc.KBD inhibited the development of diastolic dysfunction and heart failure in the Ossabaw model, without negatively impacting systolic function. The improvement in cardiac phenotype was associated with decreased T-cell myocardial infiltrates and partial reversal of pathological gene expression. An unbiased interactome study revealed that the KBD peptide binds Ca2+/calmodulin-dependent protein kinase II (CaMKII), identifying CaMKII as a new AKAP6β binding partner. Perinuclear CaMKII activity detected by live cell imaging required AKAP6β expression and was inhibited by KBD expression. In addition, the CaMKII substrate Inhibitor of NF-κB Kinase β (IKKβ) bound AKAP6β. IKK phosphorylation in the Ossabaw model and in myocytes was inhibited by KBD expression, and NF-κB nuclear translocation in myocytes was dependent upon AKAP6β-CaMKII protein complex formation. AAV9sc.KBD treatment inhibited cardiomyocyte NF-κB-dependent gene expression in the Ossabaw model. Conclusions: Regulated by perinuclear AKAP6β-CaMKII signalosomes, NF-κB pro-inflammatory gene expression in cardiomyocytes participates in a positive feedback loop with cardiac inflammation promoting HFpEF. Proof-of-concept is provided in a large animal model that gene therapy-based cardiomyocyte expression of the KBD peptide will prevent cardiac dysfunction in cardiometabolic syndrome.
Open AccessGene therapy targeting of AKAP6β-CaMKII signalosomes improves myocardial inflammation and heart failure in a swine model of cardiometabolic syndrome
Background: Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is associated with systemic and cardiac inflammation and diastolic dysfunction. A-kinase anchoring protein 6β (AKAP6β) is a scaffold protein located at the cardiomyocyte outer nuclear membrane that promotes pathological cardiac remodeling via the recruitment of multiple regulatory proteins including protein kinases. In mice, adeno-associated virus (AAV) mediated expression of a peptide based upon a kinase binding domain (KBD) within AKAP6β inhibited the development of heart failure due to chronic pressure overload. Whether KBD expression can also inhibit the development of cardiometabolic heart failure is unknown, and if so, the mechanism of KBD action in HFpEF has yet to be explored. Methods: The efficacy of a cardiotropic self-complementary AAV gene therapy that expresses the AKAP6β KBD peptide (AAV9sc.KBD) was tested in a female Ossabaw swine model of cardiometabolic syndrome and HFpEF. Single nucleus and bulk RNA sequencing of swine heart tissue and immunoprecipitation-mass spectrometry, live cell imaging, and biochemical assays using primary rat cardiomyocytes were employed to study KBD mechanism of action. Results: AAV9sc.KBD inhibited the development of diastolic dysfunction and heart failure in the Ossabaw model, without negatively impacting systolic function. The improvement in cardiac phenotype was associated with decreased T-cell myocardial infiltrates and partial reversal of pathological gene expression. An unbiased interactome study revealed that the KBD peptide binds Ca2+/calmodulin-dependent protein kinase II (CaMKII), identifying CaMKII as a new AKAP6β binding partner. Perinuclear CaMKII activity detected by live cell imaging required AKAP6β expression and was inhibited by KBD expression. In addition, the CaMKII substrate Inhibitor of NF-κB Kinase β (IKKβ) bound AKAP6β. IKK phosphorylation in the Ossabaw model and in myocytes was inhibited by KBD expression, and NF-κB nuclear translocation in myocytes was dependent upon AKAP6β-CaMKII protein complex formation. AAV9sc.KBD treatment inhibited cardiomyocyte NF-κB-dependent gene expression in the Ossabaw model. Conclusions: Regulated by perinuclear AKAP6β-CaMKII signalosomes, NF-κB pro-inflammatory gene expression in cardiomyocytes participates in a positive feedback loop with cardiac inflammation promoting HFpEF. Proof-of-concept is provided in a large animal model that gene therapy-based cardiomyocyte expression of the KBD peptide will prevent cardiac dysfunction in cardiometabolic syndrome.
- Open Access
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e044692
Targeting of Cdc42‐Interacting Protein 4‐Calcineurin Signalosomes Improves Cardiac Structure and Function After Myocardial Infarction
Background: CaN (calcineurin) promotes pathological cardiac remodeling but also cardioprotection in ischemia–reperfusion injury. CaN inhibitors are also immunosuppressants. This pleiotropy complicates targeting calcineurin in cardiovascular disease. CIP4/TRIP10 (Cdc42‐interacting protein 4) is a scaffold protein that binds the CaNAβ (calcineurin Aβ) N‐terminal polyproline domain and organizes a calcium and CaNAβ2 signaling compartment independent of contractile calcium. We showed that CIP4‐CaNAβ2 signalosomes promote pathological cardiac hypertrophy induced by pressure overload. It is unknown whether CIP4‐CaNAβ2 signalosomes contribute to cardioprotection and remodeling in ischemic disease. Methods: CIP4 conditional knockout mice were studied following ischemia–reperfusion and permanent left coronary artery ligation that induce myocardial infarction. C57BL/6NJ mice were transduced with cardiotropic adeno‐associated virus expressing a CaNAβ2 small hairpin RNA to inhibit CaNAβ2 expression, a VIVIT peptide to inhibit CaN‐NFAT (nuclear factor of activated T cells) signaling, or a CaNAβ polyproline peptide to block CIP4‐CaNAβ2 binding and similarly studied by ischemia–reperfusion injury and left coronary artery ligation. CaNAβ polyproline‐dependent signaling was also studied in T cells. Results: CIP4 conditional knockout and cardiomyocyte‐specific CaNAβ polyproline peptide expression improved cardiac function after ischemia–reperfusion injury and decreased infarct size and improved cardiac function after permanent left coronary artery ligation. In contrast, cardiomyocyte‐specific CaNAβ2 depletion and VIVIT expression worsened outcome after myocardial infarction. The polyproline peptide had no effect on T‐cell activation and cytokine expression in vitro. Conclusions: CIP4‐CaNAβ2 signalosomes promote adverse cardiac remodeling and are not cardioprotective. Proof of concept is provided for the treatment of ischemic cardiomyopathy by a polyproline peptide gene therapy. Targeting these complexes may be beneficial in cardiovascular diseases, including ischemic cardiomyopathy and acute myocardial infarction.
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e044692
Open AccessTargeting of Cdc42‐Interacting Protein 4‐Calcineurin Signalosomes Improves Cardiac Structure and Function After Myocardial Infarction
Background: CaN (calcineurin) promotes pathological cardiac remodeling but also cardioprotection in ischemia–reperfusion injury. CaN inhibitors are also immunosuppressants. This pleiotropy complicates targeting calcineurin in cardiovascular disease. CIP4/TRIP10 (Cdc42‐interacting protein 4) is a scaffold protein that binds the CaNAβ (calcineurin Aβ) N‐terminal polyproline domain and organizes a calcium and CaNAβ2 signaling compartment independent of contractile calcium. We showed that CIP4‐CaNAβ2 signalosomes promote pathological cardiac hypertrophy induced by pressure overload. It is unknown whether CIP4‐CaNAβ2 signalosomes contribute to cardioprotection and remodeling in ischemic disease. Methods: CIP4 conditional knockout mice were studied following ischemia–reperfusion and permanent left coronary artery ligation that induce myocardial infarction. C57BL/6NJ mice were transduced with cardiotropic adeno‐associated virus expressing a CaNAβ2 small hairpin RNA to inhibit CaNAβ2 expression, a VIVIT peptide to inhibit CaN‐NFAT (nuclear factor of activated T cells) signaling, or a CaNAβ polyproline peptide to block CIP4‐CaNAβ2 binding and similarly studied by ischemia–reperfusion injury and left coronary artery ligation. CaNAβ polyproline‐dependent signaling was also studied in T cells. Results: CIP4 conditional knockout and cardiomyocyte‐specific CaNAβ polyproline peptide expression improved cardiac function after ischemia–reperfusion injury and decreased infarct size and improved cardiac function after permanent left coronary artery ligation. In contrast, cardiomyocyte‐specific CaNAβ2 depletion and VIVIT expression worsened outcome after myocardial infarction. The polyproline peptide had no effect on T‐cell activation and cytokine expression in vitro. Conclusions: CIP4‐CaNAβ2 signalosomes promote adverse cardiac remodeling and are not cardioprotective. Proof of concept is provided for the treatment of ischemic cardiomyopathy by a polyproline peptide gene therapy. Targeting these complexes may be beneficial in cardiovascular diseases, including ischemic cardiomyopathy and acute myocardial infarction.
- 9 September 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (10) , 682-698
Unique Role of Intracellular Perinuclear β 1 -Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling
BACKGROUND: β-Adrenergic receptors (βARs) are prototypical G protein–coupled receptors that regulate contractility in the normal heart and pathological remodeling in disease. Canonical βAR signaling originates at the plasma membrane, but functional βARs have been localized to intracellular membranes such as the endosome, sarcoplasmic reticulum, Golgi, and nuclear envelope. The functional significance of these intracellular receptors remains unclear, including whether they regulate cellular processes distinct from those regulated by plasma membrane receptors and whether they can be independently targeted for therapeutic benefit. METHODS: Live cell imaging of rat and human cardiomyocytes expressing novel compartment-specific modulators of βAR activity and fluorescent biosensors was used to study the compartment-specific βAR regulation of second messengers and to target enzyme activity. Compartmentalized signaling was compared with myocyte gene expression and hypertrophy. Adeno-associated virus gene delivery conferring gain and loss of perinuclear βAR activity was studied in wild-type mice and a mouse model of familial dilated cardiomyopathy. RESULTS: We demonstrate here that intracellular β 1 ARs present on Golgi membrane facing the outer nuclear membrane regulate a perinuclear cAMP compartment containing the A-kinase anchoring protein 6β signalosome, conferring selective regulation of perinuclear cAMP-dependent protein kinase activity independently of βARs at the plasma membrane or endosome. The A-kinase anchoring protein 6β compartment is shown to be of nanometer scale and dependent on local restriction of cAMP diffusion. In addition, perinuclear βARs are shown to be sufficient and necessary for activation of the Ca 2+ -dependent calcineurin–nuclear factor of activated T cells pathway and myocyte hypertrophy in vitro. Accordingly, adeno-associated virus 9–based delivery of an outer nuclear membrane–localized pepducin, which selectively activated perinuclear βARs in vitro, induced dilated cardiomyopathy in wild-type mice. Conversely, in vivo delivery of an outer nuclear membrane–localized nanobody, which selectively inhibited perinuclear βARs in vitro, improved cardiac function and inhibited pathological remodeling in a mouse model of familial dilated cardiomyopathy with established disease. CONCLUSIONS: These results demonstrate that β 1 ARs localized to Golgi membranes facing the outer nuclear membrane regulate A-kinase anchoring protein 6β signalosomes required for the induction of pathological cardiac remodeling, defining an intracellular nanocompartment. Proof of concept is provided for a novel therapeutic approach for familial dilated cardiomyopathy, with potential application to other forms of cardiovascular disease.
- 9 September 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (10) , 682-698
Unique Role of Intracellular Perinuclear β 1 -Adrenergic Receptors in Defining Signaling Compartmentation and Pathological Cardiac Remodeling
BACKGROUND: β-Adrenergic receptors (βARs) are prototypical G protein–coupled receptors that regulate contractility in the normal heart and pathological remodeling in disease. Canonical βAR signaling originates at the plasma membrane, but functional βARs have been localized to intracellular membranes such as the endosome, sarcoplasmic reticulum, Golgi, and nuclear envelope. The functional significance of these intracellular receptors remains unclear, including whether they regulate cellular processes distinct from those regulated by plasma membrane receptors and whether they can be independently targeted for therapeutic benefit. METHODS: Live cell imaging of rat and human cardiomyocytes expressing novel compartment-specific modulators of βAR activity and fluorescent biosensors was used to study the compartment-specific βAR regulation of second messengers and to target enzyme activity. Compartmentalized signaling was compared with myocyte gene expression and hypertrophy. Adeno-associated virus gene delivery conferring gain and loss of perinuclear βAR activity was studied in wild-type mice and a mouse model of familial dilated cardiomyopathy. RESULTS: We demonstrate here that intracellular β 1 ARs present on Golgi membrane facing the outer nuclear membrane regulate a perinuclear cAMP compartment containing the A-kinase anchoring protein 6β signalosome, conferring selective regulation of perinuclear cAMP-dependent protein kinase activity independently of βARs at the plasma membrane or endosome. The A-kinase anchoring protein 6β compartment is shown to be of nanometer scale and dependent on local restriction of cAMP diffusion. In addition, perinuclear βARs are shown to be sufficient and necessary for activation of the Ca 2+ -dependent calcineurin–nuclear factor of activated T cells pathway and myocyte hypertrophy in vitro. Accordingly, adeno-associated virus 9–based delivery of an outer nuclear membrane–localized pepducin, which selectively activated perinuclear βARs in vitro, induced dilated cardiomyopathy in wild-type mice. Conversely, in vivo delivery of an outer nuclear membrane–localized nanobody, which selectively inhibited perinuclear βARs in vitro, improved cardiac function and inhibited pathological remodeling in a mouse model of familial dilated cardiomyopathy with established disease. CONCLUSIONS: These results demonstrate that β 1 ARs localized to Golgi membranes facing the outer nuclear membrane regulate A-kinase anchoring protein 6β signalosomes required for the induction of pathological cardiac remodeling, defining an intracellular nanocompartment. Proof of concept is provided for a novel therapeutic approach for familial dilated cardiomyopathy, with potential application to other forms of cardiovascular disease.
- Open Access
Targeting of CIP4-Calcineurin Signalosomes Improves Cardiac Structure and Function After Myocardial Infarction
Background: Calcineurin in a pleiotropic signaling enzyme that promotes pathological cardiac remodeling but also cardioprotection in ischemia-reperfusion injury. In addition, calcineurin inhibitors are immunosuppressants. This pleiotropy has precluded the use of calcineurin inhibitors as treatments for heart failure. Cdc42-interacting protein 4 (CIP4/TRIP10) is an endosomal scaffold protein that organizes a calcium and calcineurin Aβ2 (CaNAβ2) signaling compartment activated by G-protein coupled receptors independently of contractile calcium. CIP4 binds CaNAβ2 via the CaNAβ-specific N-terminal polyproline (PP) domain. We previously showed that targeting of CIP4-CaNAβ2 signalosomes inhibited pathological cardiac hypertrophy and the development of heart failure induced by chronic pressure overload in mice. It is unknown whether CIP4-CaNAβ2 signalosomes contribute to cardioprotection and/or cardiac remodeling in ischemic heart disease. Methods: CIP4 conditional knock-out (CKO) mice were studied by echocardiography with strain analysis and histology following ischemia-reperfusion (I/R) injury and permanent left coronary artery (LCA) ligation to induce myocardial infarction. Wildtype C57BL/6NJ mice were transduced with adeno-associated virus (AAV) engineered for cardiomyocyte-specific expression of either a CaNAβ2 shRNA to inhibit CaNAβ2 expression, a VIVIT peptide to inhibit CaN-NFAT signaling, or a CaNAβ2 PP peptide to block CIP4-CaNAβ2 binding. AAV-transduced mice were studied by I/R injury. Additional mice were subjected to permanent LCA ligation and subsequently treated with AAV to test the effects of CaN inhibition in chronic ischemic cardiomyopathy. The effects of CaNAβ2 PP-GFP expression on primary T-cell activation were studied in vitro . Results: CIP4 CKO mice and mice expressing the PP anchoring disruptor peptide exhibited preserved cardiac function after I/R injury and decreased infarct size and preserved cardiac function 8 weeks after myocardial infarction by permanent LCA ligation. In contrast, cardiomyocyte-specific depletion of CaNAβ2 and VIVIT peptide expression worsened outcome after I/R injury and in chronic ischemic cardiomyopathy. In addition, in contrast to cardiomyocytes, PP-mediated CaNAβ anchoring inhibition had no effect on T-cell activation and cytokine expression in vitro . Conclusions: CIP4-CaNAβ2 signalosomes promote adverse cardiac remodeling and are not cardioprotective. Proof-of-concept is provided for the treatment of ischemic cardiomyopathy by a PP anchoring disruptor gene therapy. Targeting these complexes may be beneficial in cardiovascular diseases, including ischemic cardiomyopathy and acute myocardial infarction. Clinical Perspective: What is New?: Targeting CIP4, which is a scaffold protein for the phosphatase calcineurin, improves cardiac function in mice after acute myocardial infarction due to ischemia-reperfusion injury and in chronic ischemic cardiomyopathy. Gene therapy-based expression of a calcineurin Aβ-derived polyproline peptide, which can compete CIP4-calcineurin binding, is beneficial in acute and chronic myocardial infarction. What Are the Clinical Implications?: This study establishes CIP4 signalosomes as a new drug target for the treatment of ischemia-reperfusion injury and chronic pathological cardiac remodeling. This study provides proof-of-concept for a new gene therapy approach to treating acute myocardial infarction and chronic ischemic cardiomyopathy.
Open AccessTargeting of CIP4-Calcineurin Signalosomes Improves Cardiac Structure and Function After Myocardial Infarction
Background: Calcineurin in a pleiotropic signaling enzyme that promotes pathological cardiac remodeling but also cardioprotection in ischemia-reperfusion injury. In addition, calcineurin inhibitors are immunosuppressants. This pleiotropy has precluded the use of calcineurin inhibitors as treatments for heart failure. Cdc42-interacting protein 4 (CIP4/TRIP10) is an endosomal scaffold protein that organizes a calcium and calcineurin Aβ2 (CaNAβ2) signaling compartment activated by G-protein coupled receptors independently of contractile calcium. CIP4 binds CaNAβ2 via the CaNAβ-specific N-terminal polyproline (PP) domain. We previously showed that targeting of CIP4-CaNAβ2 signalosomes inhibited pathological cardiac hypertrophy and the development of heart failure induced by chronic pressure overload in mice. It is unknown whether CIP4-CaNAβ2 signalosomes contribute to cardioprotection and/or cardiac remodeling in ischemic heart disease. Methods: CIP4 conditional knock-out (CKO) mice were studied by echocardiography with strain analysis and histology following ischemia-reperfusion (I/R) injury and permanent left coronary artery (LCA) ligation to induce myocardial infarction. Wildtype C57BL/6NJ mice were transduced with adeno-associated virus (AAV) engineered for cardiomyocyte-specific expression of either a CaNAβ2 shRNA to inhibit CaNAβ2 expression, a VIVIT peptide to inhibit CaN-NFAT signaling, or a CaNAβ2 PP peptide to block CIP4-CaNAβ2 binding. AAV-transduced mice were studied by I/R injury. Additional mice were subjected to permanent LCA ligation and subsequently treated with AAV to test the effects of CaN inhibition in chronic ischemic cardiomyopathy. The effects of CaNAβ2 PP-GFP expression on primary T-cell activation were studied in vitro . Results: CIP4 CKO mice and mice expressing the PP anchoring disruptor peptide exhibited preserved cardiac function after I/R injury and decreased infarct size and preserved cardiac function 8 weeks after myocardial infarction by permanent LCA ligation. In contrast, cardiomyocyte-specific depletion of CaNAβ2 and VIVIT peptide expression worsened outcome after I/R injury and in chronic ischemic cardiomyopathy. In addition, in contrast to cardiomyocytes, PP-mediated CaNAβ anchoring inhibition had no effect on T-cell activation and cytokine expression in vitro . Conclusions: CIP4-CaNAβ2 signalosomes promote adverse cardiac remodeling and are not cardioprotective. Proof-of-concept is provided for the treatment of ischemic cardiomyopathy by a PP anchoring disruptor gene therapy. Targeting these complexes may be beneficial in cardiovascular diseases, including ischemic cardiomyopathy and acute myocardial infarction. Clinical Perspective: What is New?: Targeting CIP4, which is a scaffold protein for the phosphatase calcineurin, improves cardiac function in mice after acute myocardial infarction due to ischemia-reperfusion injury and in chronic ischemic cardiomyopathy. Gene therapy-based expression of a calcineurin Aβ-derived polyproline peptide, which can compete CIP4-calcineurin binding, is beneficial in acute and chronic myocardial infarction. What Are the Clinical Implications?: This study establishes CIP4 signalosomes as a new drug target for the treatment of ischemia-reperfusion injury and chronic pathological cardiac remodeling. This study provides proof-of-concept for a new gene therapy approach to treating acute myocardial infarction and chronic ischemic cardiomyopathy.
- Open Access
The Unique Role of Intracellular Perinuclear β-Adrenergic Receptors in defining Signaling Compartmentation and Pathological Cardiac Remodeling
Summary: The β-adrenergic receptor is a prototypical G-protein coupled receptor that initiates signaling from the plasma membrane. However, active receptors have been detected within intracellular compartments. The functional significance of these intracellular receptors remains unclear, including whether they regulate distinct cellular processes or function independently of plasma membrane receptors. We show using live cell imaging of primary cardiomyocytes that β-adrenergic receptors localized to Golgi apparatus opposing the outer nuclear membrane are sufficient and necessary for the stimulation of cAMP and calcium signaling within a nanometer scale compartment independent of receptors at other sites. Using compartment-specific activators and inhibitors, we show Golgi β-adrenergic receptors associated with the scaffold protein AKAP6β and the outer nuclear membrane protein nesprin-1α are responsible for pathological gene transcription and the induction of cardiomyocyte hypertrophy. The functional significance of Golgi-localized receptors is demonstrated in mice models of cardiomyopathy, providing proof-of-concept for a compartment-specific therapeutic intervention in Dilated Cardiomyopathy.
Open AccessThe Unique Role of Intracellular Perinuclear β-Adrenergic Receptors in defining Signaling Compartmentation and Pathological Cardiac Remodeling
Summary: The β-adrenergic receptor is a prototypical G-protein coupled receptor that initiates signaling from the plasma membrane. However, active receptors have been detected within intracellular compartments. The functional significance of these intracellular receptors remains unclear, including whether they regulate distinct cellular processes or function independently of plasma membrane receptors. We show using live cell imaging of primary cardiomyocytes that β-adrenergic receptors localized to Golgi apparatus opposing the outer nuclear membrane are sufficient and necessary for the stimulation of cAMP and calcium signaling within a nanometer scale compartment independent of receptors at other sites. Using compartment-specific activators and inhibitors, we show Golgi β-adrenergic receptors associated with the scaffold protein AKAP6β and the outer nuclear membrane protein nesprin-1α are responsible for pathological gene transcription and the induction of cardiomyocyte hypertrophy. The functional significance of Golgi-localized receptors is demonstrated in mice models of cardiomyopathy, providing proof-of-concept for a compartment-specific therapeutic intervention in Dilated Cardiomyopathy.